英语翻译Platelet activation and aggregation plays an integral ro

英语翻译
Platelet activation and aggregation plays an integral role in the pathogenesis of acute coronary syndrome (ACS).The mainstay of ACS treatment revolves around platelet inhibition.It is known that greater platelet inhibition results in better ischemic outcomes; hence,focus in drug development has been to create more potent inhibitors of platelet aggregation.Prasugrel,a potent,third-generation thienopyridine,was approved by the US Food and Drug Administration in July 2009 for its use in ACS and percutaneous coronary intervention.The addition of prasugrel to aspirin for dual antiplatelet therapy has been shown to reduce the ischemic outcomes compared with clopidogrel and aspirin in combination.However,being a more potent antiplatelet agent,prasugrel increases the risk of bleeding,especially in those patients who are at a higher risk of bleeding complications.Elderly patients ≥75 years,patients who weigh ≥60 kg,and patients with a history of stroke or transient ischemic attack are at a higher risk of bleeding complications when prasugrel is used in combination with aspirin.Newer antiplatelets currently are being clinically evaluated to assess their efficacy in reducing ischemic events without increasing the bleeding risk.

血小板活化和聚合过程中发挥着不可或缺的作用的发病机制,急性冠脉综合征(ACS).支柱的ACS治疗围绕血小板抑制作用.众所周知,更大的血小板抑制导致更好的缺血性结果;因此,集中在药物开发已经产生了更强的抑制剂血小板聚集.普拉格雷,一个强有力的,第三代thienopyridine,是经美国食品和药物管理局在2009年7月对其使用在ACS和经皮冠状动脉介入.添加普拉格雷对阿司匹林对双重抗血小板治疗已被证明可以减少缺血性结果与氯吡格雷和阿司匹林在组合.然而,作为一个更强有力的抗血小板剂,普拉格雷增加出血的风险,尤其是在患者出血并发症的风险更高.老年患者≥75年,患者≥60公斤重,史的病人中风或短暂性缺血发作风险更高的出血并发症当普拉格雷是联合使用阿司匹林.新antiplatelets目前正在临床评估的疗效评估在减少缺血性事件不增加出血的风险.